Circulating tumor DNA (ctDNA) is the portion of the cell-free DNA in the blood of cancer patients released from tumor cells via apoptosis, necrosis, or active release. From 10 mL of blood, the 4-5 mL of plasma obtained from a cancer patient contains 5-10 ng/mL of ctDNA. The plas...
Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non–small cell ...
Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.
Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National ...
Purpose This study aimed to report the projected cancer incidence and mortality for the year 2023 to estimate Korea’s current cancer burden.
Materials and Methods Cancer incidence data from 1999 to 2020 were obtained from the Korea National Cancer Incidence Database, and cance...
